Dermatology NewsDo You Have Patients With JAKne — JAK Inhibitor–Associated Acne? Here’s What to KnowAugust 22, 2024AcnePsoriatic ArthritisPediatricsAtopic DermatitisPsoriasisMedical Dermatology
Dermatology NewsUS Experience With Infliximab Biosimilars Suggests Need for More Development IncentivesAugust 13, 2024PediatricsPsoriatic ArthritisPsoriasis
Dermatology NewsAdvantages of a Pediatric Rheumatology/Dermatology Clinic EvaluatedJuly 30, 2024PediatricsPsoriasisAutoimmune DiseasesPsoriatic Arthritis
Dermatology NewsStudy Finds Differences in Side Effect Profiles With Two Oral Psoriasis TherapiesJuly 26, 2024PsoriasisPsoriatic Arthritis
Dermatology NewsRisk of MACE Comparable Among Biologic Classes for Psoriasis, PsAJuly 26, 2024PsoriasisPsoriatic ArthritisMixed Topics
Dermatology NewsSteroids’ 75th Anniversary: Clinicians Strive to Use LessJuly 25, 2024Psoriatic ArthritisPediatricsAutoimmune Diseases
Dermatology NewsMysteries Persist About Tissue Resident Memory T Cells in PsoriasisJuly 25, 2024PsoriasisPsoriatic Arthritis
Dermatology NewsDebate: Should Dermatologists or Rheumatologists Manage Musculoskeletal Symptoms in Patients With Psoriasis?July 23, 2024PsoriasisAutoimmune DiseasesPsoriatic Arthritis
Dermatology NewsDebate Over Axial Involvement in Psoriatic Arthritis Still Unresolved Despite New StudiesJuly 2, 2024Psoriatic Arthritis
Dermatology NewsPyzchiva Receives FDA Approval as Third Ustekinumab BiosimilarJuly 2, 2024Psoriatic ArthritisPediatricsRare DiseasesPsoriasis
Dermatology NewsPsoriatic Arthritis Symptoms Relieved with TYK2 Inhibitor in Phase 2 TrialJune 28, 2024Psoriatic Arthritis
Dermatology NewsPsoriatic Arthritis Drug Candidate Sonelokimab Yields Significant Improvements in Phase 2 TrialJune 28, 2024Psoriatic Arthritis
Dermatology NewsLatest Izokibep Trial for PsA Shows Promise But Misses on EnthesitisJune 20, 2024Psoriatic Arthritis
Dermatology NewsWhat’s in a Name: Defining Difficult-to-Treat axSpA and PsAJune 14, 2024Psoriatic Arthritis
Dermatology NewsClear Coverage Preference for Humira Over Biosimilars Seen in Most Medicare Part D PlansJune 7, 2024Business of MedicinePsoriatic Arthritis
